Sort   by:  
 Page size 
UnknownCombination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells.
Not available
S-EPMC7115922 | biostudies-literature
UnknownImproved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.
Not available
S-EPMC3637210 | biostudies-literature
UnknownAblation of Wnt signaling in bone marrow stromal cells overcomes microenvironment-mediated drug resistance in acute myeloid leukemia.
Not available
S-EPMC11006665 | biostudies-literature
TranscriptomicsComparison of gene expression profile of naive versus arsenic trioxide resistant acute promyelocytic leukemia cell line NB4
The aim of this study was to gain insight into the potential mechanism of resistance to arsenic trioxide (ATO). The gene expression profile of naive (NB4) (Acute promyelocytic leukemia (APL) cell line and one of its in house generated ATO resistant sub clone (NB4-VM-AsR1) was done using whole genome...
ORGANISM(S): Homo sapiens 
2013-08-02 | E-GEOD-42031 | biostudies-arrayexpress
TranscriptomicsDifferential gene expression profile of newly diagnosed versus relapse acute promyelocytic leukemia
The aim of this study was to gain insight into the potential mechanism of resistance to arsenic trioxide and to identify genes that are modulated in the malignant promyelocytes at the time of relapse in APL patients. We analyzed the gene expression profile by the whole genome microarray of primary p...
ORGANISM(S): Homo sapiens 
2013-08-02 | E-GEOD-42030 | biostudies-arrayexpress
UnknownStromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia.
Not available
S-EPMC6769009 | biostudies-literature
UnknownReal world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
Not available
S-EPMC8803919 | biostudies-literature
TranscriptomicsBone marrow micro-environment mediated drug resistance in Acute promyelocytic leukemia
About 5-10% newly diagnosed and about 20-30% of relapsed acute promyelocytic leukemia (APL) patients will have disease recurrence after receiving currently accepted standards of care. While there are reports of micro-environment mediated drug resistance (EM-DR) in AML, there is no data on the effect...
ORGANISM(S): Homo sapiens 
2016-09-01 | E-GEOD-73157 | biostudies-arrayexpress
Sort   by:  
 Page size